

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any matter referred to in this document or as to the action you should take, you should consult an independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) if you are in the United Kingdom, or another appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom, without delay.

If you have sold or otherwise transferred all of your Shares, please send this document at once to the purchaser or transferee or to the bank, stockbroker or other agent through whom or by whom the sale or transfer was made, for delivery to the purchaser or transferee.

Notice of a General Meeting of the Company to be held at the offices of the offices of Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London, EC1A 2FG on 28 April 2026 at 12 noon, is set out at the end of this document.

Proxies may be submitted electronically using MUFG Corporate Markets' Investor Centre at <https://uk.investorcentre.mpms.mufg.com/> or via the Investor Centre app or in hard copy form if you request a hard copy form of proxy from the Company's Registrar, MUFG Corporate Markets. In order to be valid, proxy appointments must be submitted using MUFG Corporate Markets' Investor Centre or in hard copy form to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, in each case, by no later than 12 midday on 24 April 2026 or 48 hours before any adjourned meeting.

CT HEALTHCARE TRUST PLC

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

Notice of Annual General Meeting

If you require a hard copy form of proxy (or assistance with how to complete, sign and return it) or assistance in submitting your proxy appointment electronically, please email MUFG Corporate Markets on shareholderenquiries@cm.mpms.mufg.com or call on 0371 664 0300 and +44 (0) 371 664 0300 (international). Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales.

If you hold your Shares in uncertificated form (i.e. in CREST) you may appoint a proxy for the Annual General Meeting by completing and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual issued by Euroclear so that it is received by the Registrar (under CREST Participation ID RA10) by no later than 12 midday on 24 April 2026. The time of receipt will be taken to be the time from which the Registrar is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

If you are an institutional investor you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed upon by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io.

PART 1

LETTER FROM THE CHAIRMAN

CT Healthcare Trust Plc

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

Directors:

Kate Bolsover (Chairman)
Josephine Dixon
Professor Tony Young OBE
Clare Brady
Sarah MacAulay

Registered Office:

4th Floor
46-48 James Street
London
W1U 1EZ

26 March 2026

To Shareholders

Dear Sir or Madam

Annual General Meeting

INTRODUCTION

The ninth Annual General Meeting of the CT Healthcare Trust plc (formerly Bellevue Healthcare Trust plc) will be held at the offices of Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London EC1A 2FG on 28 April 2026 at 12 noon. The business to be considered at the Annual General Meeting is contained in the Notice of Annual General Meeting beginning on page 7 of this document. A brief explanation of each of the Resolutions to be considered is set out below.

This letter explains the business to be considered at the Annual General Meeting and includes a recommendation that you vote in favour of the resolutions set out in the notice of the Annual General Meeting.

This is the Company's first Annual General Meeting since the appointment of Columbia Threadneedle Investments as the Company's investment manager. As part of the proposals approved by Shareholders in relation to the appointment of Columbia Threadneedle Investments, the Board was granted the authority to allot and issue (or sell from treasury) new Shares equal to up to 100 per cent. of the Company's existing issued share capital (excluding Shares held in treasury) as at 12 February 2025, and to disapply pre-emption rights in respect of such Shares (the "**Share Issuance Authorities**"). The Share Issuance Authorities expire at the conclusion of the Company's Annual General Meeting in 2027, or the date which falls 15 months after the date on which this Resolution is passed, whichever is the earlier. Accordingly, the Board will not be seeking any additional authorities to allot, issue or sell further Shares from treasury at the Annual General Meeting, though it intends to do so on an annual basis going forwards.

ORDINARY RESOLUTIONS

Resolution 1: The Directors must lay the annual audited financial statements for the financial year ended 30 November 2025 and the reports of the Directors and the Auditor thereon before Shareholders, and the Shareholders will be asked to receive and consider the financial statements and the reports ("**Annual Report and Accounts**").

Resolution 2: Shareholders will be asked to receive and approve the Directors' Implementation Report included in the in the Annual Report and Accounts for the year ended 30 November 2025. The Directors' Remuneration Implementation Report is set out in full on page 43 of the Annual Report and Accounts.

The Directors' Remuneration Implementation Report is put forward for approval by Shareholders on an annual basis. The result of the Shareholder resolution on the Implementation Report is non-binding on the Company, although it gives Shareholders an opportunity to express their views and the Board will take feedback regarding remuneration and incorporate this into any future remuneration discussions.

Resolutions 3 to 5 (inclusive):

As announced on 30 October 2025, in addition to acting as Chairman of the Company, Kate Bolsover is also the Chairman of another company of which Columbia Threadneedle Investments acts as investment manager. Accordingly, following the appointment of Columbia Threadneedle Investments as the Company's investment manager on 5 March 2026, Kate can no longer be considered independent of Columbia Threadneedle Investments for the purposes of the UK Listing Rules. In order to ensure that both companies remain in compliance with the UK Listing Rules and adhere to the highest standards of corporate governance, Kate will not be standing for re-election at the Annual General Meeting.

Sarah MacAulay, who joined the Board in February 2025, will be appointed as the next Chairman of the Company with effect from the conclusion of this Annual General Meeting (subject to her re-election as a director).

Jo Dixon will conclude her service as Senior Independent Director at the Annual General Meeting upon reaching the end of her tenure. A search process is underway to appoint a new non-executive director to the Board, with the Senior Independent Director role to be determined in due course as part of the Board's succession planning process.

In accordance with the Articles and corporate governance best practice as set out in the AIC Code of Corporate Governance, all Directors will retire from office at the Annual General Meeting. Each Director, other than Kate Bolsover and Jo Dixon, has offered himself or herself to stand for re-election. Each Director re-elected will hold office until the conclusion of the next Annual General Meeting due to be held in 2027 unless in the meantime he or she retires or ceases to be a Director in accordance with the Articles, by operation of law or until he or she resigns.

Following a performance evaluation of the Directors, the Board believes that each Director standing for re-election continues to make an effective and valuable contribution and demonstrates commitment to the role. Biographical details of all the Directors standing for re-election appear on pages 37 and 38 of the Annual Report and Accounts.

Resolutions 6 and 7: Following the outcome of a tender process in relation to the appointment of the Company's external auditors, shareholders will be asked to confirm the appointment of BDO LLP as the Company's auditors until the conclusion of the next Annual General Meeting due to be held in 2027 and to grant authority to the Board to determine the auditors' remuneration.

Resolution 8: The Directors are pleased to recommend, and the Shareholders are requested to approve, a final dividend of 2.70p per Share, payable to those shareholders whose names appear on the Register of Members at close of business on 8 May 2026. If the final dividend is approved, it is proposed to be paid on 29 May 2026.

SPECIAL RESOLUTIONS

Resolution 9: As part of the Company's discount management arrangements, the Directors are seeking authority for the Company to purchase from time to time its own Shares in the market up to 8,444,794 Shares (equivalent to 14.99 per cent. of the Shares in issue (excluding shares held in treasury)) as at the date of this document or, if different, such amount as represents 14.99 per cent. of the Company's issued share capital (excluding shares held in treasury) at the date of the passing of Resolution 9, either for cancellation or to hold as treasury shares for future resale or transfer.

Purchases will only be made in the market at prices at or below the prevailing net asset value per Ordinary Share in circumstances in which the Directors believe such purchases should result in an increase in the net asset value per Share of the remaining Shares or as a means of addressing any imbalance between the supply of, and demand for, Shares.

The Board intends to seek renewal of this authority at subsequent annual general meetings in accordance with current best practice. As at the date of this document, the Company holds 258,816,122 Shares in treasury.

Resolution 10: Resolution 10 is a resolution to allow the Company to call general meetings (other than the Company's annual general meeting) on 14 clear days' notice.

Under the Companies (Shareholders' Rights) Regulations 2009 and the Companies (Shareholders Rights to Voting Confirmations) Regulations 2020, traded companies such as the Company must provide 21 clear days' notice of a general meeting, unless, amongst other things, shareholders approve the holding of general meetings on 14 clear days' notice on an annual basis. The Company does not intend to use this shorter notice period as a matter of routine for such meetings but is seeking the flexibility to do so where merited by the business of the meeting in question and where the Board considers it to be in the best interests of Shareholders as a whole.

ACTION TO BE TAKEN IN RESPECT OF THE ANNUAL GENERAL MEETING

Shareholders are requested to appoint a proxy whether or not they wish to attend the Annual General Meeting. The appointment of a proxy will not prevent Shareholders from attending the Annual General Meeting and voting in person should they so wish.

Please submit your vote by proxy electronically using MUFG Corporate Markets' Investor Centre at <https://uk.investorcentre.mpms.mufg.com/> or via the Investor Centre app or in hard copy form if you request a hard copy form of proxy from the Company's Registrar, MUFG Corporate Markets. In order to be valid, proxy appointments must be submitted using MUFG Corporate Markets' Investor Centre share portal service or in hard copy form to MUFG Corporate Markets at PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL, in each case, by no later than midday on 24 April 2026 or 48 hours before any adjourned meeting.

If you require a hard copy form of proxy (or assistance with how to complete, sign and return it) or assistance in submitting your proxy appointment electronically, please email MUFG Corporate Markets: shareholderenquiries@cm.mpms.mufg.com, or call on 0371 664 0300 and +44 (0) 371 664 0300 (international). Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m. Monday to Friday, excluding public holidays in England and Wales.

If you hold your Shares in uncertificated form (i.e. in CREST), you may appoint a proxy for the Annual General Meeting by completing and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual issued by Euroclear so that it is received by the Registrar (under CREST Participation ID RA10) by no later than midday on 24 April 2026. The time of receipt will be taken to be the time from which the Registrar is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

If you are an institutional investor, you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed upon by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io.

A quorum for the Annual General Meeting consisting of two Shareholders present (in person or by attorney or proxy or, in the case of a corporation Shareholder, by a duly appointed representative) and entitled to vote is required for the Annual General Meeting.

Resolutions 1 to 8 are proposed as ordinary resolutions, which, on a poll, require a simple majority of more than 50 per cent of the total voting rights cast on the relevant resolution (excluding any votes that are withheld) to be in favour.

Resolutions 9 and 10 are proposed as special resolutions, which, on a poll, require not less than 75 per cent. of the total voting rights cast on the relevant resolution (excluding any votes that are withheld) to be in favour.

RECOMMENDATION

The Board considers the proposals and subjects of all of the Resolutions set out in this document to be in the best interests of the Company and its Shareholders as a whole. Accordingly, the Board unanimously recommends that Shareholders vote in favour of the Resolutions to be proposed at the Annual General Meeting.

The Directors intend to vote in favour of the Resolutions in respect of their holdings of Shares, amounting to 230,301 Shares in aggregate (representing approximately 0.44 per cent. of the issued share capital of the Company as at the date of this document, excluding Shares held in treasury).

Yours faithfully

Kate Bolsover

(Chairman)

PART 2

DEFINITIONS

In this document the words and expressions listed below have the meanings set out opposite them, except where the context otherwise requires:

Articles	the articles of association of the Company, as amended from time to time
Company	CT Healthcare Trust plc
CREST	the relevant system as defined in the CREST Regulations in respect of which Euroclear is the operator (as defined in the CREST Regulations) in accordance with which securities may be held in uncertificated form
Directors or Board	the board of directors of the Company
Euroclear	Euroclear UK & International Limited
Annual General Meeting	the annual general meeting of the Company to be held at the offices of Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London, EC1A 2FG on 28 April 2026 at 12 noon for the purpose of considering and, if thought fit, approving the Resolutions
Register of Members	the register of members of the Company
Registrar	MUFG Corporate Markets
Resolutions	the ordinary and special resolutions to be proposed at the Annual General Meeting
Shareholder	a holder of Shares
Shares	ordinary redeemable shares of £0.01 each in the capital of the Company

NOTICE OF ANNUAL GENERAL MEETING

CT Healthcare Trust Plc

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

Notice is hereby given that the annual general meeting of CT Healthcare Trust plc (the "**Company**") will be held on 28 April 2026 at 12 noon at the offices of Hogan Lovells International LLP, Atlantic House, Holborn Viaduct, London, EC1A 2FG for the following purposes:

To consider and if thought fit pass the following resolutions of which resolutions 1 to 8 will be proposed as ordinary resolutions and resolutions 9 and 10 will be proposed as special resolutions.

ORDINARY RESOLUTIONS

1. To receive the Company's Annual Report and Accounts for the year ended 30 November 2025, with the reports of the Directors and auditors thereon.
2. To approve the Directors' Remuneration Implementation Report included in the Company's annual report for the year ended 30 November 2025.
3. To re-elect Tony Young as a Director of the Company.
4. To re-elect Clare Brady as a Director of the Company
5. To re-elect Sarah MacAulay as a Director of the Company.
6. To appoint BDO LLP as auditors to the Company.
7. To authorise the Directors to fix the remuneration of the auditors until the conclusion of the next annual general meeting of the Company.
8. To approve a final dividend of 2.70p per Ordinary Share of the Company in respect of the year ended 30 November 2025.

SPECIAL RESOLUTIONS

9. That, in substitution for any existing authority, but without prejudice to the exercise of any authority prior to the date hereof, the Company be and is hereby generally and unconditionally authorised in accordance with section 701 of the Companies Act 2006 (the "**Act**") to make market purchases (within the meaning of section 693(4) of the Act) of its ordinary shares of 1 penny each in the capital of the Company, provided that:
 - (a) the maximum number of ordinary shares hereby authorised to be purchased shall be 8,444,794 or, if different, such number as represents 14.99% of the Company's issued ordinary share capital (excluding shares held in treasury) at the date of the passing of this resolution;
 - (b) the minimum price (exclusive of any expenses) which may be paid for an ordinary share is 1 pence;
 - (c) the maximum price (excluding expenses) which may be paid for an ordinary share is not more than the higher of: (i) an amount equal to 5% above the average of the middle market quotations for an ordinary share for the five business days immediately before the day on which it purchases that share; and (ii) the higher of the price of the last independent trade and the highest current independent bid for the ordinary shares;
 - (d) the authority hereby conferred shall expire at the conclusion of the annual general meeting of the Company to be held in 2027 or, if earlier, on the expiry of 15 months from the passing of this resolution, unless such authority is renewed prior to such time; and

- (e) the Company may make a contract to purchase ordinary shares under the authority hereby conferred prior to the expiry of such authority, which will or may be executed wholly or partly after the expiration of such authority and may make a purchase of ordinary shares pursuant to any such contract as if the authority hereby conferred had not expired.
10. That a general meeting of the Company other than an annual general meeting may be called on not less than 14 clear days' notice, provided that this authority shall expire at the conclusion of the Company's next Annual General Meeting after the date of the passing of this resolution.

By Order of the Board

NSM Funds (UK) Limited
Company Secretary

Dated 26 March 2026

Registered Office:
4th Floor
46-48 James Street
London
W1U 1EZ

Notes:

1. WEBSITE ADDRESS

Information regarding the meeting, including the information required by section 311A of the Companies Act 2006, is available from www.columbiathreadneedle.co.uk/ct-healthcare-trust/

2. ENTITLEMENT TO ATTEND AND VOTE

Only those holders of ordinary shares registered in the Company's Register of Members at close of business on 26 April 2026, or, if this meeting is adjourned, at close of business on the day two days prior to the adjourned meeting, shall be entitled to attend and vote at the meeting.

Should a shareholder have a question that they would like to raise at the AGM, either of the Board or the Investment Manager, the Board would ask that they either ask the question in advance of the AGM by sending it by email to InvestmentTrustCompanySecretaries@columbiathreadneedle.com or attending the AGM and asking the question at the meeting at the appropriate time. Answers to all questions will be published on the Company's website after the Annual General Meeting.

3. APPOINTMENT OF PROXIES

If you are a member of the Company at the time set out in note 2 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the meeting. You can appoint a proxy using only the procedures set out in these notes and the notes to the proxy form.

A proxy does not need to be a member of the Company but must attend the meeting to represent you. If you wish your proxy to speak on your behalf at the meeting you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.

Pursuant to Section 324 of the Companies Act 2006, you may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please indicate on your proxy submission how many shares it relates to.

A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.

4. APPOINTMENT OF PROXY USING HARD COPY FORM

A hard copy form of proxy has not been sent to you but you can request one directly from the Registrar's, MUFG Corporate Markets' general helpline team 0371 664 0300 and +44 (0) 371 664 0300 (international). Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales. Alternatively, you can request a hard copy form of proxy via email at shareholderenquiries@cm.mpms.mufg.com or via postal address at MUFG Corporate Markets, PXS 1, Central Square, 29 Wellington Street, Leeds LS1 4DL. In the case of a member which is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.

5. APPOINTMENT OF PROXY ONLINE

Shareholders can vote electronically via the Investor Centre, a free app for smartphone and tablet provided by MUFG Corporate Markets (the company's registrar). It allows you to securely manage and monitor your shareholdings in real time, take part in online voting, keep your details up to date, access a range of information including payment history and much more. The app is available to download on both the Apple App Store and Google Play, or by scanning the relevant QR code below. Alternatively, you may access the Investor Centre via a web browser at: <https://uk.investorcentre.mpms.mufg.com/>.



You will need to log into your Investor Centre account or register if you have not previously done so. Once you have setup your account you will need to add your shareholding by clicking 'Add Holding' in the 'Portfolio' section and following the on-screen instructions. You will require your Investor Code (IVC) to add your shareholding. You can find your IVC on your share certificate or by contacting our Registrar, MUFG Corporate Markets. If you need help with voting online, please contact MUFG Corporate Markets on 0371 664 0300 and +44 (0) 371 664 0300 (international) or via email at shareholderenquiries@cm.mpms.mufg.com. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales.

6. APPOINTMENT OF PROXY THROUGH CREST

CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the meeting to be held on the above date and any adjournment(s) thereof by using the procedures described in the CREST Manual. CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "**CREST Proxy Instruction**") must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the Company's agent (ID: RA10) by the latest time(s) for receipt of proxy appointments specified below. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

7. APPOINTMENT OF PROXY THROUGH PROXYMITY

If you are an institutional investor, you may also be able to appoint a proxy electronically via the Proxymity platform, a process which has been agreed upon by the Company and approved by the Registrar. For further information regarding Proxymity, please go to www.proxymity.io. Your proxy must be lodged by 12 midday on 24 April 2026 in order to be considered valid or, if the meeting is adjourned, by the time which is 48 hours before the time of the adjourned meeting. Before you can appoint a proxy via this process you will need to have agreed to Proxymity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy. An electronic proxy appointment via the Proxymity platform may be revoked completely by sending an authenticated message via the platform instructing the removal of your proxy vote.

8. APPOINTMENT OF PROXY BY JOINT MEMBERS

In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's Register of Members in respect of the joint holding, the first-named being the most senior.

9. CHANGING PROXY INSTRUCTIONS

To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off times for receipt of proxy appointments (see above) also apply in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded. Where you have appointed a proxy using a hard copy proxy form and would like to change the instructions using another hard copy proxy form, please contact MUFG Corporate Markets as per the communication methods shown in note 4. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

10. TERMINATION OF PROXY APPOINTMENTS

In order to revoke a proxy instruction, you will need to inform the Company by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to MUFG Corporate Markets, at the address shown in note 4. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed, or a duly certified copy of such power or authority, must be included with the revocation notice. The revocation notice must be received by MUFG Corporate Markets no later than 48 hours before the meeting.

11. NOMINATED PERSONS

If you are a person who has been nominated under section 146 of the Companies Act 2006 to enjoy information rights:

- (a) You may have a right under an agreement between you and the member of the Company who has nominated you to have information rights ("**Relevant Member**") to be appointed or to have someone else appointed as a proxy for the meeting.
- (b) If you either do not have such a right or if you have such a right but do not wish to exercise it, you may have a right under an agreement between you and the Relevant Member to give instructions to the Relevant Member as to the exercise of voting rights.
- (c) Your main point of contact in terms of your investment in the Company remains the Relevant Member (or, perhaps, your custodian or broker) and you should continue to contact them (and not the Company) regarding any changes or queries relating to your personal details and your interest in the Company (including any administrative matters). The only exception to this is where the Company expressly requests a response from you.

If you are not a member of the Company but you have been nominated by a member of the Company to enjoy information rights, you do not have a right to appoint any proxies.

Corporate representatives are entitled to attend and vote on behalf of the corporate member in accordance with Section 323 of the Companies Act 2006 provided they do not do so in relation to the same shares.

12. QUESTIONS AT THE MEETING

Under section 319A of the Companies Act 2006, the Company must answer any question you ask relating to the business being dealt with at the meeting unless:

- (a) answering the question would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information;
- (b) the answer has already been given on a website in the form of an answer to a question; or
- (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

13. ISSUED SHARES AND TOTAL VOTING RIGHTS

As at 23 March 2026, (being the latest practicable date prior to the date of this notice) the total number of shares in issue is 56,336,187 shares of 1 pence each and an additional 258,816,122 shares were held in treasury. The total number of shares with voting rights is therefore 56,336,187. On a vote by a show of hands, every holder of shares who (being an individual) is present in person, by proxy or (being a corporation) is present by a duly authorised representative, not being himself a member, shall have one vote. On a poll every holder of shares who is present in person or by proxy shall have one vote for every share held by him.

14. COMMUNICATION

Except as provided above, members who have general queries about the meeting should use the following means of communication (no other methods of communication will be accepted):

- (a) calling MUFG Corporate Markets' shareholder helpline (lines are open from 9.00 a.m. to 5.30 p.m. Monday to Friday, excluding public holidays):
 - (i) From UK: 0371 664 0300 (calls are charged at the standard geographic rate and will vary by provider);
 - (ii) From Overseas: +44 371 664 0300 (calls from outside the UK are charged at applicable international rates); or
- (b) in writing to MUFG Corporate Markets; or
- (c) by email to MUFG Corporate Markets on shareholderenquiries@cm.mpms.mufg.com.

You may not use any electronic address provided either in this notice of meeting or in any related documents (including the form of proxy for this meeting) to communicate with the Company for any purposes other than those expressly stated.

